Related Experiment Video
Updated: Jan 4, 2026
08:15
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
19.9K
Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure
Bishoy Abraham1, Michael Megaly2, Mina Sous3
1Department of Medicine, Ascension Saint John Hospital, Detroit, Michigan.
The American Journal of Cardiology
|November 9, 2019
Summary
Torsemide offers improved functional status and reduced cardiac mortality in heart failure patients compared to furosemide. While hospitalizations were numerically lower with torsemide, overall mortality and side effects showed no significant difference between the two diuretics.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Torsemide's pharmacokinetic profile suggests potential advantages over furosemide as a diuretic.
- Clinical data comparing the efficacy and safety of torsemide and furosemide in heart failure management remain limited.
Purpose of the Study:
- To systematically review and analyze the comparative clinical outcomes of torsemide versus furosemide in patients with heart failure.
- To assess differences in hospitalization rates, functional status, mortality, and adverse events.
Main Methods:
- A systematic review and meta-analysis of published studies comparing torsemide and furosemide in heart failure patients.
- Included 19 studies (9 RCTs, 10 observational) with 19,280 patients, from January 1996 to August 2019.
Main Results:
- Torsemide use was linked to significantly greater improvement in New York Heart Association functional class (NYHA III/IV to I/II) and a lower risk of cardiac mortality compared to furosemide.
- A numerically lower risk of heart failure hospitalization was observed with torsemide, though not statistically significant.
- No significant differences were found in all-cause mortality or medication side effects between the two groups.
Conclusions:
- Torsemide demonstrates superior efficacy in improving functional status and reducing cardiac mortality in heart failure patients compared to furosemide.
- Torsemide may offer a clinical benefit in reducing heart failure hospitalizations, warranting further investigation.
- Both diuretics appear to have similar safety profiles regarding overall mortality and side effects.
Related Concept Videos
01:30Heart Failure V: Medical Management
186
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
186
01:22Heart Failure Drugs: Diuretics
759
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
759
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
863
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
863
01:29Heart Failure II: Pathophysiology
638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
01:22Heart Failure VI: Adjunct Therapies
220
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
220
01:30Heart Failure IV: Classification and Diagnostic Evaluation
274
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
274